M42 has officially launched a large-scale pilot program in Abu Dhabi involving 10,000 patients to integrate continuous wearable health monitoring into routine clinical practice. By tracking 5,000 individuals with diabetes and another 5,000 with kidney disease, the company aims to move beyond traditional, episodic care. This initiative allows doctors to monitor patients in real-time, helping them identify subtle changes in health status before they escalate into emergencies—a critical shift for renal patients who often experience significant physiological fluctuations between their scheduled dialysis sessions.

This project is a key component of Abu Dhabi’s broader strategy to create a unified health ecosystem that bridges the gap between genomic research, real-world data, and clinical intervention. By utilizing advanced AI that can predict complications like vascular-access thrombosis, M42 is building a system where biological insights are paired with daily lifestyle metrics. According to health officials, the ultimate goal is to translate these technological breakthroughs into practical, life-saving patient pathways, ensuring that early data detection is immediately met with proactive medical support rather than remaining confined to the research lab.